GLYCODIP

TAB GLYCODIP-500 SR (Metformin 500 mg (SR)) BILSTER 10 X 10
TAB GLYCODIP 1000 SR (Metformin 1000 mg (SR)) BILSTER 10 X 10
Category: Tag:

Introduction:

GLYCODIP is a targeted monotherapy option based on Metformin Sustained Release (SR), the cornerstone of Type 2 Diabetes Mellitus (T2DM) management. Metformin is globally recommended as the first-line oral antidiabetic agent due to its proven efficacy, safety profile, and metabolic benefits. The SR formulation ensures better gastrointestinal tolerability and once-daily dosing, improving patient compliance.

All variants are available in blister packs (10 x 10 tablets) to ensure dosage convenience and protection from environmental exposure.


Product Variants & Composition:

GLYCODIP-500 SR
Composition: Metformin 500 mg (Sustained Release)
Packaging: Blister | 10 x 10 Tablets

GLYCODIP 1000 SR
Composition: Metformin 1000 mg (Sustained Release)
Packaging: Blister | 10 x 10 Tablets


Key Benefits:

  • Metformin SR: Offers a gradual release for better gastrointestinal tolerance and extended glycemic control.

  • Reduces hepatic glucose production and improves insulin sensitivity in muscles.

  • Promotes weight neutrality or mild weight loss—ideal for overweight T2DM patients.

  • Lowers HbA1c effectively without causing hypoglycemia.

  • Enhances lipid profiles and reduces cardiovascular risk factors.

  • Safe and effective for long-term monotherapy or as part of combination therapy.


Indications:

  • Newly diagnosed Type 2 Diabetes Mellitus

  • Overweight/obese individuals with insulin resistance

  • Suitable as monotherapy or adjunct to sulfonylureas, DPP-4 inhibitors, or insulin


Dosage & Administration:

  • Typically started at 500 mg once daily, with gradual titration based on glycemic response.

  • Recommended to be taken with meals to minimize gastrointestinal side effects.

  • Dosage should be personalized with regular monitoring of blood glucose and renal function.


Precautions & Warnings:

  • Not for use in Type 1 Diabetes or Diabetic Ketoacidosis.

  • Avoid in patients with renal impairment (eGFR <30 ml/min/1.73m²).

  • Caution in hepatic dysfunction or alcohol abuse due to risk of lactic acidosis.

  • Discontinue temporarily before contrast imaging or major surgery.


Possible Side Effects:

  • Gastrointestinal upset: nausea, diarrhea, flatulence (usually transient)

  • Metallic taste

  • Rare: Lactic acidosis, especially in renal dysfunction


Conclusion:

The GLYCODIP range offers effective and well-tolerated Metformin SR therapy for foundational glycemic control in T2DM. With its convenient SR formulations, GLYCODIP improves metabolic outcomes while minimizing side effects and enhancing adherence.

Note : Always Consult a physician before taking any medication, and do not rely solely on this information for medical advice.

For more such product information and similar product category Diabetic

You can also contact us  https://diabetes-cardiac.com/contact-us/